Hao Luo

Title: Hao Luo - Innovator in Peptide Compounds Targeting PD-1 Receptor

Introduction

Hao Luo is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of peptide compounds, particularly those targeting the PD-1 receptor. His innovative work has implications for the development of analgesic drugs.

Latest Patents

Hao Luo holds a patent for "Peptide compounds targeting PD-1 receptor as well as preparation and applications thereof." This patent includes a peptide compound that consists of five distinct compounds, each containing amino acid sequences identical to SEQ ID NO: 1-5. The preparation method involves a solid-phase synthesis technique, which allows for the efficient coupling of amino acids to a solid-phase resin. The resulting target compound is obtained through cleavage, freeze-drying, and preparative purification. The compounds are designed to bind to the PD-1 receptor and demonstrate significant inhibitory effects on inflammatory and visceral pain when administered intrathecally. They are noted for their simplicity in synthesis, ease of purification, and suitability for large-scale production. Hao Luo has 1 patent to his name.

Career Highlights

Hao Luo is affiliated with Nantong University, where he continues to advance his research in peptide compounds. His work is characterized by a focus on practical applications in pain management and drug development.

Collaborations

Hao Luo collaborates with notable colleagues, including Gang Chen and Long Zhao, who contribute to his research endeavors.

Conclusion

Hao Luo's innovative work in peptide compounds targeting the PD-1 receptor showcases his commitment to advancing medical science and improving pain management therapies. His contributions are paving the way for future developments in this critical area of research.